The pharma industry faces downsizing in various areas, where a number of employees are fired or relieved of their duties. These job cuts are driven by a number of factors, such as financial pressures and the diversifying product portfolio
The recent layoffs are not a result of a complete shutdown in the industry and lack of investor trust, but the industry's realignment in response to the adoption of new technology, development of latest drugs, and the replacement of traditional manufacturing practices with new innovative & intelligent procedures.
In addition to the manufacturing industry, the FDA also faces job and funding cuts. As with the manufacturing sector, these factors are related to finances and to restructure the entire agency.
Like other regulatory bodies, the FDA does not generate its finances, and funding and has to rely on the government to cover different expenses. It is possible that the cuts in FDA could lead to slow decision-making and fewer drug approvals, in contrast to the previous practice.
A brief overview of each FDA and manufacturing industry job cut
FDA
In April this year, the federal government laid off approximately 3500 employees of the FDA. These layoffs are a part of 10,000 job cuts at the Department of Health and Human Services. The layoffs are for personnel working in departments that include vaccine, medical devices, and veterinary.
Types of layoffs that affect include
· Staff responsible for writing guidance documents
· Staff responsible for the information industry about their questions and application review status
· Test products for adulteration
· Staff responsible for issuing press releases, updating the FDA website, and informing consumers about health risks and new product approvals
Official Position
The US President Trump announced an executive order, "Implementing the President's 'Department of Government Efficiency' Workforce Optimization Initiative," for restructuring the Department of Health and Human Services. To comply with this order, among other
· Saving taxpayers $1.8 billion annually, by reducing the workforce to 10,000 full-time employees, resulting in a total reduction of about 62,000 full-time employees
· Currently, 28 divisions of HHS will be reduced to 15 new divisions.
· This restructuring will improve Americans' experience with the agency.
· It will prioritize HHS to end the chronic disease epidemic by focusing on safe, wholesome food, clean water, and eliminating environmental toxins.
Pharma Manufacturing Organizations
Pharmaceutical manufacturing is a stronger entity in the industry, and any change impacts the industry as a whole. Layoffs are also happening in pharma manufacturing, mainly due to economic uncertainties and new business strategies.
No specific type of pharma manufacturing organization is affected by the recent cuts. All types of industry, such as manufacturing, R&D, equipment, and CDM, O types have been affected.
Some significant reasons for downsizing include the following.
· Planning cost reduction due to uncertainties globally.
· Exploring business opportunities in fields other than the usual & traditional ones
· Failure to achieve targets for existing business or inability to reach the timeline previously set
· Restructuring the current management or board due to many reasons, such as to improve the current performance, or completion of tenure
Some details of layoffs and job cuts related to pharma manufacturing include the following.
· Unity Biotechnology plans to lay off all its human resources to pursue alternatives after the phase 2 trial results of UBX1325.
· Mammoth Biosciences also laid off about 24 employees in a move to improve its internal programs, improve partnerships, and explore new research in therapeutics.
· Pliant Therapeutics laid off 45% of its staff for safety reasons in its late-stage respiratory drug.
· Arvinas is planning to cut 33% of its staff after its partner and it are dropping two phase 3 trials.
·...
(All Rights Reserved)